Top

Published in:

01-05-2014 | Research Article

MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis

Authors: Zhi-xiong Qiu, Fei Xue, Xuan-feng Shi, Xiao He, Hui-ni Ma, Lan Chen, Pin-zhong Chen

Published in: Tumor Biology | Issue 5/2014

Abstract

Many studies have examined the association between the MGMT Leu84Phe polymorphism gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. To assess this relationship more precisely, a meta-analysis was performed. The PubMed and CNKI database was searched for case–control studies published up to Nov. 2013. Data were extracted and pooled odds ratios (OR) with 95 % confidence intervals (CI) were calculated. Ultimately, 7 studies, comprising 3,094 lung cancer cases and 4,216 controls, were included. Overall, for (Phe/Phe+Phe/Leu) versus Leu/Leu, the pooled OR for all studies was 1.08 (95 % CI = 0.97–1.21 P = 0.518 for heterogeneity); for Phe/Phe versus Leu/Leu and Phe versus Leu, the pooled OR was 1.10 (95 % CI = 0.99–1.21 P = 0.445 for heterogeneity) and 1.46 (95 % CI = 1.05–2.02 P = 0.352 for heterogeneity), respectively. In the stratified analysis by ethnicity, significantly risks were found among Caucasians not in Asians. This meta-analysis suggests that the MGMT Leu84Phe polymorphisms are associated with lung cancer risk among Caucasians not in Asians.

Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21–49.CrossRef

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentral

Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–51.CrossRefPubMed

Daniels DS, Woo TT, Luu KX, Noll DM, Clarke ND, et al. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat Struct Mol Biol. 2004;11:714–20.CrossRefPubMed

Chae MH, Jang JS, Kang HG, Park JH, Park JM, Lee WK, et al. O6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer. Mol Carcinog. 2006;45:239–49.CrossRefPubMed

Hall J, Hashibe M, Boffetta P, Gaborieau V, Moullan N, Chabrier A, et al. The association of sequence variants in DNA repair and cell cycle genes with cancers of the upper aerodigestive tract. Carcinogenesis. 2007;28:665–71.CrossRefPubMed

Han J, Hankinson SE, DeVio I. Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis. 2006;27:2281–5.CrossRefPubMed

Hazra A, Chanock S, Giovannucci E, Cox DG, Niu T, Fuchs C, et al. Large-scale evaluation of genetic variants in candidate genes for colorectal cancer risk in the Nurses’ Health Study and the Health Professionals’ Follow-up Study. Cancer Epidemiol Biomarkers Prev. 2008;17:311–9.CrossRefPubMed

Huang J, Ye F, Chen H, Lu W, Xie X. Amino acid substitution polymorphisms of the DNA repair gene mgmt and the susceptibility to cervical carcinoma. Carcinogenesis. 2007;28:1314–22.CrossRefPubMed

10.

Huang WY, Chow WH, Rothman N, Lissowska J, Llaca V, Yeager M, et al. Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis. 2005;26:1354–9.CrossRefPubMed

11.

Shen J, Terry MB, Gammon MD, Gaudet MM, Teitelbaum SL, Eng SM, et al. MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants, and breast cancer risk. Carcinogenesis. 2005;26:2131–7.CrossRefPubMed

12.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

13.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

14.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed

15.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–7.

16.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentral

17.

Hung RJ, Baragatti M, Thomas D, McKay J, Szeszenia-Dabrowska N, Zaridze D, et al. Inherited predisposition of lung cancer: a hierarchical modeling approach to DNA repair and cell cycle control pathways. Cancer epidemiology, biomarkers and prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16: 2736–44.

18.

Wang L, Liu H, Zhang Z, Spitz MR, Wei Q. Association of genetic variants of O6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites. Cancer epidemiology, bio-markers and prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15: 2364–9.

19.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27(3):560–7.CrossRefPubMed

20.

Liu RQ, Zhuang ZX. Single-nucleotide polymorphisms of human O6-methylguanine-DNA methyltransferase (MGMT) gene in lung cancer patients from south china. Wei Sheng Du Li Xue Za Zhi. 2002;16:1–5.

21.

Krześniak M, Butkiewicz D, Samojedny A, Chorazy M, Rusin M. Polymorphisms in TDG and MGMT genes—epidemiological and functional study in lung cancer patients from Poland. Ann Hum Genet. 2004;68:300–12.CrossRefPubMed

22.

Hu Z, Wang H, Shao M, Jin G, Sun W, et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum Mutat. 2007;28:431–40.CrossRefPubMed

23.

Hirschhorn JN, Lohmueller K, Byrne E. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61.CrossRefPubMed

24.

Liu J, Zhang R, Chen F, Yu C, Sun Y, Jia C, et al. MGMT Leu84Phe polymorphism contributes to cancer susceptibility: evidence from 44 case–control studies. PLoS One. 2013;8(9):e75367.CrossRefPubMedPubMedCentral

25.

Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, et al. Family history and risk of fatal prostate cancer. Epidemiology. 1997;8:653–9.CrossRefPubMed

Title: MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis
Authors: Zhi-xiong Qiu
Fei Xue
Xuan-feng Shi
Xiao He
Hui-ni Ma
Lan Chen
Pin-zhong Chen
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1576-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis

MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies

Letter regarding Wen X.Y. et al. entitled “Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis”

Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer

Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case–control studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer